DK162525C
(da)
*
|
1983-07-15 |
1992-03-30 |
Richter Gedeon Vegyeszet |
Fremgangsmaade til fremstilling af ranitidin-hydroklorid
|
GB8629781D0
(en)
*
|
1986-12-12 |
1987-01-21 |
Glaxo Group Ltd |
Pharmaceutical compositions
|
SE8704436D0
(sv)
*
|
1987-11-13 |
1987-11-13 |
Pm Konsult Handelsbolag |
Anvendning av antisekretoriska substanser for nya indikationer
|
IL90245A
(en)
*
|
1988-05-11 |
1994-04-12 |
Glaxo Group Ltd |
Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
|
GB8904182D0
(en)
*
|
1989-02-23 |
1989-04-05 |
Glaxo Canada |
Pharmaceutical compositions
|
US5169864A
(en)
*
|
1991-11-15 |
1992-12-08 |
Baxter International Inc. |
Unbuffered premixed ranitidine formulation
|
US5338871A
(en)
*
|
1991-12-20 |
1994-08-16 |
Torcan Chemical Ltd. |
Preparation of form 1 ranitidine hydrochloride
|
CN1048984C
(zh)
*
|
1991-12-20 |
2000-02-02 |
多坎化学有限公司 |
晶形1呋喃硝胺氢氯化物的制备
|
SK283674B6
(sk)
*
|
1993-03-12 |
2003-11-04 |
Pharmacia & Upjohn Company |
Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje
|
DE4341310A1
(de)
*
|
1993-12-03 |
1995-06-08 |
Hexal Pharma Gmbh |
Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
|
US5407687A
(en)
*
|
1994-02-22 |
1995-04-18 |
Glaxo Inc. |
Ranitidine solid dosage form
|
CA2120874E
(en)
*
|
1994-04-08 |
2002-01-08 |
Keshava Murthy |
Form of form 1 ranitidine
|
EP0754182A1
(en)
*
|
1994-04-08 |
1997-01-22 |
Brantford Chemicals Inc. |
Form 1 ranitidine hydrochloride with increased density
|
DE69523447T2
(de)
|
1994-04-15 |
2002-05-16 |
Pharmacia & Upjohn Co., Kalamazoo |
Kristallformen von 1-[5-methansulfonamidoindolyl-2-carbonyl]-4-[3-[1-methylethylamino]-2-pyridinyl] piperazin
|
IN181699B
(el)
*
|
1994-05-13 |
1998-09-05 |
Ranbaxy Lab Ltd |
|
NZ272054A
(en)
*
|
1994-05-13 |
1996-05-28 |
Ranbaxy Lab Ltd |
Process for producing form 1 ranitidine hydrochloride
|
IN181698B
(el)
*
|
1994-05-13 |
1998-09-05 |
Ranbaxy Lab Ltd |
|
US20030045722A1
(en)
*
|
1994-05-18 |
2003-03-06 |
Henton Daniel R. |
Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
|
CA2449419C
(en)
*
|
1994-05-18 |
2011-09-06 |
Aventis Pharmaceuticals Inc. |
Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
|
ES2122387T3
(es)
|
1994-06-24 |
1998-12-16 |
Ranbaxy Lab Ltd |
Procedimiento para la preparacion de la forma 1 del clorhidrato de ranitidina.
|
AU709057B2
(en)
*
|
1994-11-18 |
1999-08-19 |
Pharmacia & Upjohn Company |
A new physically stable solid form of a fluoroquinolone
|
US5538737A
(en)
*
|
1994-11-30 |
1996-07-23 |
Applied Analytical Industries, Inc. |
Oral compositions of H2 -antagonists
|
US5663381A
(en)
*
|
1995-04-21 |
1997-09-02 |
Hexal Pharmaceuticals, Inc. |
Process for preparing form 1 ranitidine hydrochloride
|
US5686588A
(en)
*
|
1995-08-16 |
1997-11-11 |
Yoo; Seo Hong |
Amine acid salt compounds and process for the production thereof
|
WO1997035853A1
(en)
*
|
1996-03-25 |
1997-10-02 |
Hoechst Marion Roussel, Inc. |
Process for the preparation of form 1 ranitidine hydrochloride
|
ES2150808T3
(es)
*
|
1997-08-08 |
2000-12-01 |
Aventis Pharma Gmbh |
Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
|
US6287693B1
(en)
|
1998-02-25 |
2001-09-11 |
John Claude Savoir |
Stable shaped particles of crystalline organic compounds
|
IT1317858B1
(it)
|
2000-02-29 |
2003-07-15 |
Pharmexcel S R L |
Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
|
GB2357762B
(en)
*
|
2000-03-13 |
2002-01-30 |
Lundbeck & Co As H |
Crystalline base of citalopram
|
US20020183553A1
(en)
*
|
2000-10-19 |
2002-12-05 |
Ben-Zion Dolitzky |
Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
|
US6569887B2
(en)
*
|
2001-08-24 |
2003-05-27 |
Dov Pharmaceuticals Inc. |
(−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
|
US20060173064A1
(en)
*
|
2001-08-24 |
2006-08-03 |
Lippa Arnold S |
(-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
|
US7235655B2
(en)
*
|
2002-03-22 |
2007-06-26 |
Pharmacia & Upjohn Company |
Processes to prepare eplerenone
|
AR040661A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Theravance Inc |
Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
|
US20080081834A1
(en)
|
2002-07-31 |
2008-04-03 |
Lippa Arnold S |
Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
|
US7166641B2
(en)
*
|
2002-10-02 |
2007-01-23 |
Yung Shin Pharmaceutical Industrial Co., Ltd. |
Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
|
RU2005117630A
(ru)
*
|
2002-11-08 |
2006-01-20 |
Дов Фармасьютикал, Инк. (Us) |
Полиморфы гидрохлорида бицифадина
|
TW200510277A
(en)
*
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
US7384557B2
(en)
*
|
2003-07-14 |
2008-06-10 |
Applied Ambient Extraction Process Consultants, Llc |
Method and apparatus for removing solute from a solid solute-bearing product
|
TWI328006B
(en)
*
|
2003-12-26 |
2010-08-01 |
Nissan Chemical Ind Ltd |
Crystal form of quinoline compound and process for its production
|
US20070043100A1
(en)
*
|
2005-08-16 |
2007-02-22 |
Hagen Eric J |
Novel polymorphs of azabicyclohexane
|
US20060100263A1
(en)
*
|
2004-11-05 |
2006-05-11 |
Anthony Basile |
Antipyretic compositions and methods
|
US20060100271A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Keith Whitehead |
Stabilized aqueous ranitidine compositions
|
RU2008107336A
(ru)
*
|
2005-07-27 |
2009-09-10 |
Дов Фармасьютикал, Инк. (Us) |
Новые 1-арил-з-азабицикло{3.1.0.} гексаны: получение и применение для лечения психоневрологических расстройств
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20080045725A1
(en)
|
2006-04-28 |
2008-02-21 |
Murry Jerry A |
Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
|
NZ576355A
(en)
*
|
2006-10-20 |
2012-04-27 |
Scinopharm Singapore Pte Ltd |
Process for making crystalline anhydrous docetaxel
|
US8138377B2
(en)
|
2006-11-07 |
2012-03-20 |
Dov Pharmaceutical, Inc. |
Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
|
US9133159B2
(en)
|
2007-06-06 |
2015-09-15 |
Neurovance, Inc. |
1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
|
WO2008153937A2
(en)
*
|
2007-06-06 |
2008-12-18 |
Dov Pharmaceutical, Inc. |
Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
|
TW201011043A
(en)
|
2008-06-20 |
2010-03-16 |
Chugai Pharmaceutical Co Ltd |
Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
|
KR20140027944A
(ko)
*
|
2011-06-30 |
2014-03-07 |
도레이 카부시키가이샤 |
글리신 유도체의 결정 및 그 의약 용도
|
US20140206740A1
(en)
|
2011-07-30 |
2014-07-24 |
Neurovance, Inc. |
Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
|
CN106432149B
(zh)
*
|
2015-05-26 |
2018-04-17 |
烟台市华文欣欣医药科技有限公司 |
一种制备治疗胃病的药物盐酸雷尼替丁化合物的方法
|
CN105030694A
(zh)
*
|
2015-08-04 |
2015-11-11 |
青岛蓝盛洋医药生物科技有限责任公司 |
一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
|
CN104971053A
(zh)
*
|
2015-08-05 |
2015-10-14 |
青岛蓝盛洋医药生物科技有限责任公司 |
一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
|
CN105055331A
(zh)
*
|
2015-08-31 |
2015-11-18 |
青岛蓝盛洋医药生物科技有限责任公司 |
一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
|
WO2021079183A1
(en)
*
|
2019-10-21 |
2021-04-29 |
Sms Pharmaceuticals Limited |
Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity
|